DaShenLin Pharmaceutical Group (603233) Fair Value & Analysis
Healthcare · CN · Market cap 19.1B CNY
Fair value as of: Jul 11, 2026
From 26 valuation models · updated 30 days ago
Share price −1.7% over the past month.
A solid business, screening 36% undervalued on our models.
What matters now
- The price is below even our cautious bear case (¥17.90). The market is more pessimistic than our downside scenario.
- Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.
How to read this chart
60‑month range ¥12.01 – ¥53.19 · fair‑value band ¥17.90 – ¥29.83 · the ¥17.51 price screens below the ¥23.86 fair value. Dashed = 300-day average. As of Jul 11, 2026.
Analysis
DaShenLin Pharmaceutical Group (603233) currently trades at ¥17.51, while our model-based Fair Value estimate is ¥23.86, implying the stock looks roughly 36.3% undervalued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, DaShenLin Pharmaceutical Group generated revenue of 27.5B CNY at a net margin of 4.7%. Revenue grew 0.2% year over year. It earns a return on equity of 15.8%. Net debt stands at 104M CNY. Fundamentals as of Jul 11, 2026
Our scenario range runs from ¥17.90 (bear case) to ¥29.83 (bull case); at ¥17.51, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at 36%, 603233 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥67.29) versus Asset-Based (¥4.33). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities.
Full company description
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
DaShenLin Pharmaceutical Group reported revenue of ¥27.5B in FY2025 versus ¥16.8B in FY2021, a compound +13.2%/yr. Reported net income was ¥1.2B in FY2025, compounding +11.8%/yr from FY2021.
Watch 603233: get an alert when its fair value changes →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.34 | ¥5.91 | -56% |
Compare DaShenLin Pharmaceutical Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is DaShenLin Pharmaceutical Group (603233) overvalued or undervalued?
What is the fair value of 603233?
What is the quality score of 603233?
What is the revenue of DaShenLin Pharmaceutical Group (603233)?
What is the net profit margin of 603233?
Does DaShenLin Pharmaceutical Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track DaShenLin Pharmaceutical Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.